[1].Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Presented at the American Society of Clinical Oncology Annual Meeting; June 2, 2023;...
[1].Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Presented at the America...
添加参考文献: NitzU,GluzO,ClemensM,etal.WestGermanStudyPlanBTrial:Adjuvantfourcyclesofepirubicinandcyclophosphamideplus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer. J Clin Oncol 2019;37:799-808. NCC...
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 4.2024, July 3, 2024 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 5.2023, December 5, 2023
>>>根据2024 v4 NCCN 指南,SG 被明确列为 mTNBC 二线治疗的全人群 1 类优选推荐,即 SG 可用于在转移性阶段接受过至少一种既往治疗方案的 mTNBC 患者。 >>>2024年更新的 ESMO 转移性乳腺癌在线指南v. 1.1版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)将 SG 治疗 mTNBC 的 ESMO 临床获益量表...
11月11日,美国国家综合癌症网络(NCCN)更新了乳腺癌2024.V6版本指南[1],与2024.V5版本相比仅有细微改动。本次更新的主要内容为: 新增inavolisib+哌柏西利+氟维司群一线治疗晚期PIK3CA激活突变、激素受体(HR)阳性/人表皮生长因子受体2(HER2)阴性乳腺癌的适应证。
2022.v4 NCCN临床实践指南:乳腺癌.pdf,® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Breast Cancer Version 4.2022 — June 21, 2022 NCCN.org ® NCCN Guidelines for Patients available at /patients Continue ® ® ® Version 4.2
BINV-20 NCCN Guidelines Version 4.2020 Invasive Breast Cancer NCCN Guidelines Index Table of Contents Discussion 复发性或 IV 期 (M1) 疾病的系统治疗 ER 和/或 PR 阳性;HER2 阴性,cc 参见 BINV-20 加用denosumab,唑存在骨病来膦酸酸或...
b.出自“Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council 2006”。可登陆以下网站获取信息:...
>>>根据2024 v4 NCCN 指南,SG 被明确列为 mTNBC 二线治疗的全人群 1 类优选推荐,即 SG 可用于在转移性阶段接受过至少一种既往治疗方案的 mTNBC 患者。 >>>2024年更新的 ESMO 转移性乳腺癌在线指南v. 1.1版(ESMO Metastatic Breast Cancer Living Guideline V. 1.1)将 SG 治疗 mTNBC 的 ESMO 临床获益量表...